Clinical Trials on Dengue Virus

Total 23486 results

Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Diseases

Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Disease

Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Diseases

Peru
Sanofi Pasteur, a Sanofi Company

Completed

Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Diseases

Singapore
Sanofi Pasteur, a Sanofi Company

Completed

Efficacy and Safety of Dengue Vaccine in Healthy Children

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Diseases

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America

Dengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

Puerto Rico, Colombia, Mexico, Honduras
Sanofi

Completed

Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

United States
Sanofi

Completed

Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects

Dengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

Australia
University of the Philippines
World Health Organization; University of North Carolina; International Vaccine... and other collaborators

Active, not recruiting

Dengue Serostatus Study in the Philippines

Dengue | Dengue Fever | Severe Dengue | Virologically-confirmed Dengue
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)

Dengue Virus | Dengue Disease

United States, Australia, Canada, Finland, Germany, Israel, Taiwan
U.S. Army Medical Research and Development Command
GlaxoSmithKline

Completed

A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Shock Syndrome

Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule

Dengue Fever | Dengue Hemorrhagic Fever

Singapore
Sanofi Pasteur, a Sanofi Company
United States Department of Defense

Completed

Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

United States
Indonesia University

Unknown

Resuscitation With Albumin 5% in Dengue Haemorrhagic Fever

Dengue Hemorrhagic

Indonesia
Oxford University Clinical Research Unit, Vietnam
Children's Hospital Number 1, Ho Chi Minh City, Vietnam; Hospital for Tropical... and other collaborators

Completed

Laboratory Diagnosis and Prognosis of Severe Dengue

Dengue Fever

Vietnam
University of the Philippines
Sanofi Pasteur, a Sanofi Company; Research Institute for Tropical Medicine,...

Completed

Dengue Effectiveness Study in the Philippines

Dengue | Severe Dengue | Virologically Confirmed Dengue

Philippines
U.S. Army Medical Research and Development Command
Walter Reed Army Institute of Research (WRAIR); Naval Medical Research Center; Vic...

Completed

Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease (TVDV)

Dengue Fever | Dengue Disease

United States
Phramongkutklao College of Medicine and Hospital

Completed

Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients

Dengue | Dengue With Warning Signs | Dengue Shock Syndrome

Thailand
National University Hospital, Singapore
Tan Tock Seng Hospital; Ng Teng Fong General Hospital

Completed

Prospective Study for the Evaluation of Dengue Prognostic Biomarkers in Singapore

Dengue Hemorrhagic Fever | Severe Dengue | Dengue Shock Syndrome

Singapore
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus

Dengue Hemorrhagic Fever | Dengue Shock Syndrome

United States
Centre Hospitalier Universitaire de la Réunion

Active, not recruiting

Factors Associated With Hospitalization for Dengue and Dengue Severity: Hospital-based Cohort Study on Reunion Island (DENGUE-RUN)

Dengue Fever With Warning Signs

France
National Institute of Allergy and Infectious Diseases...
Johns Hopkins Bloomberg School of Public Health

Completed

Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus

Dengue Hemorrhagic Fever

United States
Serum Institute of India Pvt. Ltd.
PPD Australia Pty Ltd

Completed

A Phase 1 Safety Study of Dengusiil in Healthy Adults

Prevention of Dengue Fever

Australia
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers

Dengue | Dengue Hemorrhagic Fever

Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America

Dengue | Dengue Hemorrhagic Fever

Brazil
Mahidol University

Completed

Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients (PKIDEN)

Dengue Hemorrhagic Fever

Thailand
Bangabandhu Sheikh Mujib Medical University, Dhaka...

Recruiting

Role of Vitamin D in Prevention of Dengue Haemorrhagic Fever and Dengue Shock Syndrome

Dengue Fever

Bangladesh
Sanofi Pasteur, a Sanofi Company

Completed

Association of Host Genetics With Vaccine Efficacy and Study of Immune Correlates of Risk From a Tetravalent Dengue Vaccine

Dengue Fever | Dengue Haemorrhagic Fever

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

India
Sanofi Pasteur, a Sanofi Company

Completed

Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

Thailand
Sanofi Pasteur, a Sanofi Company

Terminated

Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects

Dengue Fever | Dengue Hemorrhagic Fever

Philippines
Sanofi

Completed

Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia

Dengue Fever | Dengue Hemorrhagic Fever

Malaysia
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

Colombia, Puerto Rico, Brazil, Honduras, Mexico
Sanofi

Completed

A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines

Dengue Fever | Dengue Hemorrhagic Fever

Philippines
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

Indonesia, Philippines, Malaysia, Thailand, Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia

Dengue Fever | Dengue Hemorrhagic Fever

Australia
U.S. Army Medical Research and Development Command

Active, not recruiting

Comparison of Tetravalent Dengue Virus Purified Inactivated Vaccine and Tetravalent Dengue Virus Live Attenuated Vaccine

Dengue Virus

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine

Dengue Virus

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immune Response to an Investigational Dengue Type 2 Vaccine

Dengue Virus

United States
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine

Dengue Fever | Dengue Hemorrhagic Fever

Brazil, Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age

Dengue Fever | Dengue Hemorrhagic Fever

Colombia, Philippines
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule

Dengue Fever | Dengue Hemorrhagic Fever

Brazil, Colombia, Honduras, Mexico, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

India
Ilocos Training and Regional Medical Center

Not yet recruiting

Effectiveness Of High Dose Melatonin As Adjunctive Therapy For Dengue Fever With Warning Signs

Dengue Fever With Warning Signs
Sanofi Pasteur, a Sanofi Company

Completed

Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine

Yellow Fever | Dengue | Dengue Fever | Dengue Hemorrhagic Fever

United States
Sanofi Pasteur, a Sanofi Company

Completed

Observational Study to Evaluate the Safety of CYD Tetravalent Dengue Vaccine (CYD-TDV) in Pregnant Women and Their Offsprings Inadvertently Exposed During Pregnancy

Dengue Virus Infection

Brazil
Innogene Kalbiotech Pte. Ltd

Unknown

Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS)

Dengue Shock Syndrome

Indonesia
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®

Dengue Fever | Dengue Hemorrhagic Fever | Human Papillomavirus Disease

Malaysia
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®

Dengue Fever | Dengue Hemorrhagic Fever | Human Papillomavirus Disease

Mexico
Le Phuoc Truyen

Recruiting

NT-proBNP and Troponin I in Dengue Children

Children, Only | Dengue Shock Syndrome

Vietnam

Clinical Trials on Dengue Virus

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations